Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension Trial

Summary

A multicenter, non-randomized, open label trial, to assess long term safety and efficacy of Arimoclomol in subjects with Amyotrophic Lateral Sclerosis (ALS) who have completed the ORARIALS-01 trial.

Timeline

Start

2019-09-19

Primary completion

2021-07-02

Completion

2021-07-02

Outcome

Outcome not reported

Stopped: “As a consequence of the results of ORARIALS-01 which did not meet any of its efficacy endpoints. The planned duration was 152 weeks. After termination, the actual mean duration of treatment was approx. 28 weeks (range approx. 2 to 71 weeks).”

Drugs

Indications